What are the differences between early phase trial design and late phase trial design? What are some common assumptions for early trial designs? What are some challenges for statistics nowadays?

Dr. Brian Smith will answer all these questions for you. Brian got his Phd in statistics from the University of Kentucky and has been actively involved in promoting quantitative sciences in drug development. He has a diverse background in biostatistics and has held numerous positions in the pharmaceutical industry and academia. He currently holds the position of executive director of Biostatistics at Novartis.

Throughout his career, Brian has focused on early clinical development in the pharmaceutical industry. He has played an active role in the development and implementation of statistical methods to improve the efficiency and quality of drug development. With his vast experience and expertise in biostatistics, Brian has become a respected leader in the field and continues to contribute to the advancement of quantitative sciences in drug development. Let’s dive into this episode and see what Brian shared with us.

Please visit our website https://biostatisticspodcast.github.io/ for the latest updates and transcripts of the published episodes.
If you have any comments, feedback or suggestions, feel free to email us via biostatisticspodcast@gmail.com or DM us on Twitter @BiostatsPodcast